N/A
N=1,584
Impact of an Atrial Fibrillation Decision Support Tool (AFDST) on Thromboprophylaxis for Atrial Fibrillation
Atrial Fibrillation · Atrial Flutter
Bottom Line
View on ClinicalTrials.gov: NCT02524977 ↗Enrolled (actual)
1,584
Serious AEs
0.0%
Results posted
Oct 2018
Primary outcome: Primary: Changes in Discordant Antithrombotic Therapy — 291; 335; 277; 329 participants — p=0.02
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Decision Support (Behavioral); Educational Intervention Only (Behavioral)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- University of Cincinnati
- Primary completion
- Mar 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Changes in Discordant Antithrombotic Therapy |
291; 335; 277; 329 | 0.02 sig |
| SECONDARY Antithrombotic Therapy Discordant From AFDST Among Patients for Whom AFDST Report Was Reviewed |
152; 140 | — |
Summary
Study objective was to improve decision-making and thromboprophylaxis for patients with Atrial Fibrillation (AF) by developing and implementing a computerized decision support tool for individual patient-level decision-making about oral anticoagulant therapy. To accomplish these goals, the investigators studied the incremental impact of adding a quality-improvement (QI) intervention to an educational package (for practice staff and clinicians) using a computerized aid, the Atrial Fibrillation Decision Support Tool (AFDST) for individual patient-level decision-making about oral anticoagulant therapy in patients with non-valvular AF. The decision support tool incorporates individual patients' risk factor profiles for ischemic stroke and bleeding and provides a recommendation for treatment based upon the projected quality-adjusted life expectancy gained or lost with the addition of either oral anticoagulant therapy or aspirin compared with no thromboprophylaxis.
Eligibility Criteria
Inclusion Criteria
- Study subjects were physicians in our primary care network.
- Patients included in the study were identified through our health system's clinical data store with an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), diagnosis of atrial fibrillation (427.31) or atrial flutter (427.32)
Exclusion Criteria
Diagnoses of mitral valve disease (394.x), aortic valve disease (395.x), heart valve transplant (V42.2) or heart valve replacement (V42.3).
Data sourced from ClinicalTrials.gov (NCT02524977). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.